

22 September 2005



**National Institute for
Health and Clinical Excellence**

MidCity Place
71 High Holborn
London
WC1V 6NA

Tel: +44 (0)20 7067 5800

Fax: +44 (0)20 7067 5801

nice@nice.org.uk

www.nice.org.uk

Dear Sir or Madam

Health Technology Appraisal

Review of NICE Technology Appraisal Guidance No.47, glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes

Further to our letter of 18 July, we would like to update you on the decision made regarding the review of the existing guidance on glycoprotein IIb/IIIa inhibitors. The Institute was proposing that the decision to review the guidance be deferred until July 2007, which coincides with the review date set for the guidance on clopidogrel for acute coronary syndromes (no.80).

During consultation, all of the comments received by the Institute agreed with the proposal put forward, and therefore, the Institute's Guidance Executive has decided to proceed with the proposal. We will contact you again in mid 2007, with proposals for how we might proceed with the review of the guidance. Information on this approach will be published on the Institute's website (www.nice.org.uk) on 29 September 2005.

Yours faithfully

Dr Carole Longson
Director, Centre for Health Technology Evaluation

National Institute for Health and Clinical Excellence
Letter notifying decision on review proposal for NICE Technology Appraisal Guidance No.47, glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
Issue Date: September 2005

If you have any queries regarding this correspondence please contact Clifford Middleton by email at clifford.middleton@nice.org.uk or by phone at 020 7067 5917.